BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16845449)

  • 1. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.
    Malinin A; Pokov A; Swaim L; Kotob M; Serebruany V
    Methods Find Exp Clin Pharmacol; 2006 Jun; 28(5):315-22. PubMed ID: 16845449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition.
    Lordkipanidzé M; Pharand C; Nguyen TA; Schampaert E; Diodati JG
    Ther Drug Monit; 2008 Jun; 30(3):372-8. PubMed ID: 18520610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
    Jakubowski JA; Payne CD; Li YG; Brandt JT; Small DS; Farid NA; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.
    von Beckerath N; Sibbing D; Jawansky S; Braun S; Morath T; Vogt W; Schömig A; Kastrati A
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):46-52. PubMed ID: 19823079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions.
    Rudez G; Bouman HJ; van Werkum JW; Leebeek FW; Kruit A; Ruven HJ; ten Berg JM; de Maat MP; Hackeng CM
    Circ Cardiovasc Genet; 2009 Oct; 2(5):515-21. PubMed ID: 20031628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
    Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.
    Angiolillo DJ; Costa MA; Shoemaker SB; Desai B; Bernardo E; Suzuki Y; Charlton RK; Zenni MM; Guzman LA; Bass TA
    Am J Cardiol; 2008 Feb; 101(4):440-5. PubMed ID: 18312754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.
    Bidet A; Jais C; Puymirat E; Coste P; Nurden A; Jakubowski J; Nurden P
    Platelets; 2010; 21(2):94-100. PubMed ID: 20148735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
    Varenhorst C; James S; Erlinge D; Braun OO; Brandt JT; Winters KJ; Jakubowski JA; Olofsson S; Wallentin L; Siegbahn A
    Am Heart J; 2009 Mar; 157(3):562.e1-9. PubMed ID: 19249429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy.
    Saraf S; Wellsted D; Sharma S; Gorog DA
    Thromb Res; 2009 Sep; 124(4):447-51. PubMed ID: 19476973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
    Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.